S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
Enterprise Products: 7.33% Yield and 26-Years of Dividend Growth
New AI Stock Payouts (Ad)
A Tech Stock You've Never Heard Of Just Hit The Rally Button
Challenges Hit Broadcom Stock, But Analysts See EPS Growth
New AI Stock Payouts (Ad)
Is New IPO Instacart Already Hitting Speed Bumps?
Prospect Capital Corporation: A Gold Nugget or Value Trap?
New AI Stock Payouts (Ad)
52-week Low Names To Tip The Upside Scale In Your Favor
Seagen, Activision Blizzard rise; Scholastic, Intel fall, Friday, 9/22/2023
S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
Enterprise Products: 7.33% Yield and 26-Years of Dividend Growth
New AI Stock Payouts (Ad)
A Tech Stock You've Never Heard Of Just Hit The Rally Button
Challenges Hit Broadcom Stock, But Analysts See EPS Growth
New AI Stock Payouts (Ad)
Is New IPO Instacart Already Hitting Speed Bumps?
Prospect Capital Corporation: A Gold Nugget or Value Trap?
New AI Stock Payouts (Ad)
52-week Low Names To Tip The Upside Scale In Your Favor
Seagen, Activision Blizzard rise; Scholastic, Intel fall, Friday, 9/22/2023
S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
Enterprise Products: 7.33% Yield and 26-Years of Dividend Growth
New AI Stock Payouts (Ad)
A Tech Stock You've Never Heard Of Just Hit The Rally Button
Challenges Hit Broadcom Stock, But Analysts See EPS Growth
New AI Stock Payouts (Ad)
Is New IPO Instacart Already Hitting Speed Bumps?
Prospect Capital Corporation: A Gold Nugget or Value Trap?
New AI Stock Payouts (Ad)
52-week Low Names To Tip The Upside Scale In Your Favor
Seagen, Activision Blizzard rise; Scholastic, Intel fall, Friday, 9/22/2023
S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
Enterprise Products: 7.33% Yield and 26-Years of Dividend Growth
New AI Stock Payouts (Ad)
A Tech Stock You've Never Heard Of Just Hit The Rally Button
Challenges Hit Broadcom Stock, But Analysts See EPS Growth
New AI Stock Payouts (Ad)
Is New IPO Instacart Already Hitting Speed Bumps?
Prospect Capital Corporation: A Gold Nugget or Value Trap?
New AI Stock Payouts (Ad)
52-week Low Names To Tip The Upside Scale In Your Favor
Seagen, Activision Blizzard rise; Scholastic, Intel fall, Friday, 9/22/2023
NASDAQ:DMTK

DermTech (DMTK) Stock Forecast, Price & News

$1.65
-0.05 (-2.94%)
(As of 09/22/2023 ET)
Compare
Today's Range
$1.62
$1.69
50-Day Range
$1.64
$3.79
52-Week Range
$1.55
$6.44
Volume
125,706 shs
Average Volume
472,946 shs
Market Capitalization
$55.61 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$6.33

DermTech MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.75 Rating Score
Upside/​Downside
283.8% Upside
$6.33 Price Target
Short Interest
Bearish
16.34% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.66mentions of DermTech in the last 14 days
Based on 5 Articles This Week
Insider Trading
Selling Shares
$42,134 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($3.56) to ($2.65) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.85 out of 5 stars

Medical Sector

789th out of 965 stocks

Medical Laboratories Industry

20th out of 23 stocks


DMTK stock logo

About DermTech (NASDAQ:DMTK) Stock

DermTech, Inc., a molecular diagnostic company, develops and markets novel non-invasive genomics tests to aid in the diagnosis and management of various skin conditions, including skin cancer and inflammatory diseases in the United States. The company provides DermTech Melanoma Test (DMT), an innovative non-invasive way to enhance melanoma detection for developing product for non-melanoma skin cancers. It also offers DermTech Smart Sticker, which provides a non-invasively way to collect skin sample including standard care by using scalpel to biopsy suspicious lesions. In addition, it provides research services and technology platform on a contract basis to pharmaceutical companies which use the technology for clinical trials. Further, the company develops gene expression assays for the Th1, Th2, IFN-gamma, and Th17 inflammatory pathways to pharmaceutical companies to develop drug products in dermatology; and develop custom gene assays to support the pharmaceutical partners. It sells its products through pathology and oncology practitioners. DermTech, Inc. is headquartered in San Diego, California.

DMTK Price History

DMTK Stock News Headlines

One penny stock I’m having second thoughts about
66,000% upside on tiny biotech?
The Wall Street Journal reports that this medical breakthrough is "Transforming Medicine." One analyst calculated that it could be worth $1 Trillion, making the upside potential of this small-cap 66,000% above today's price.
Insider Sell: DermTech Inc CFO Kevin Sun Sells 9,616 Shares
66,000% upside on tiny biotech?
The Wall Street Journal reports that this medical breakthrough is "Transforming Medicine." One analyst calculated that it could be worth $1 Trillion, making the upside potential of this small-cap 66,000% above today's price.
DermTech Appoints Mark Aguillard as Chief Commercial Officer
DermTech Reports Second-Quarter 2023 Financial Results
DermTech (DMTK) Gets a Buy from Craig-Hallum
Why DermTech Shares Are Rising Today
See More Headlines
Receive DMTK Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for DermTech and its competitors with MarketBeat's FREE daily newsletter.

DMTK Company Calendar

Last Earnings
8/03/2023
Today
9/22/2023
Next Earnings (Estimated)
11/02/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Medical laboratories
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:DMTK
Fax
N/A
Employees
278
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$6.33
High Stock Price Forecast
$8.00
Low Stock Price Forecast
$5.00
Forecasted Upside/Downside
+283.8%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.75
Research Coverage
4 Analysts

Profitability

Net Income
$-116,680,000.00
Net Margins
-853.02%
Pretax Margin
-853.02%

Debt

Sales & Book Value

Annual Sales
$14.52 million
Book Value
$4.38 per share

Miscellaneous

Free Float
31,981,000
Market Cap
$55.61 million
Optionable
Not Optionable
Beta
2.22
10 Best Cheap Stocks to Buy Now Cover

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

  • Mr. Kevin Sun M.B.A. (Age 45)
    CFO, Treasurer & Sec.
    Comp: $461.92k
  • Ms. Claudia IbarraMs. Claudia Ibarra (Age 61)
    Chief Operating Officer
    Comp: $414.09k
  • Mr. Ray Akhavan Esq. (Age 54)
    J.D., Gen. Counsel
    Comp: $413.06k
  • Mr. Bret Christensen (Age 52)
    Pres, CEO & Director
  • Mr. William W. Zondler
    Chief Information Officer
  • Mr. Steve E. Kunszabo
    Sr. Director of Investor Relations
  • Ms. Jennifer Eilemberg
    Chief Compliance Officer
  • Mr. Ray Bassi
    VP of Sales
  • Dr. Burkhard Jansen M.D. (Age 57)
    Chief Medical Affairs Officer
  • Mr. Daniel Visage
    Sr. VP of Payer Access













DMTK Stock - Frequently Asked Questions

Should I buy or sell DermTech stock right now?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for DermTech in the last year. There are currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" DMTK shares.
View DMTK analyst ratings
or view top-rated stocks.

What is DermTech's stock price forecast for 2023?

4 brokers have issued twelve-month price targets for DermTech's stock. Their DMTK share price forecasts range from $5.00 to $8.00. On average, they expect the company's share price to reach $6.33 in the next year. This suggests a possible upside of 283.8% from the stock's current price.
View analysts price targets for DMTK
or view top-rated stocks among Wall Street analysts.

How have DMTK shares performed in 2023?

DermTech's stock was trading at $1.77 at the beginning of the year. Since then, DMTK stock has decreased by 6.8% and is now trading at $1.65.
View the best growth stocks for 2023 here
.

When is DermTech's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, November 2nd 2023.
View our DMTK earnings forecast
.

How were DermTech's earnings last quarter?

DermTech, Inc. (NASDAQ:DMTK) announced its earnings results on Thursday, August, 3rd. The company reported ($0.99) earnings per share for the quarter, missing analysts' consensus estimates of ($0.95) by $0.04. The company earned $3.98 million during the quarter, compared to the consensus estimate of $3.55 million. DermTech had a negative trailing twelve-month return on equity of 99.14% and a negative net margin of 853.02%.

What other stocks do shareholders of DermTech own?

Based on aggregate information from My MarketBeat watchlists, some companies that other DermTech investors own include Pfizer (PFE), CrowdStrike (CRWD), DocuSign (DOCU), ONEOK (OKE), Intel (INTC), U.S. Xpress Enterprises (USX), Valero Energy (VLO), Hello Group (MOMO), AVEO Pharmaceuticals (AVEO) and Camping World (CWH).

What is DermTech's stock symbol?

DermTech trades on the NASDAQ under the ticker symbol "DMTK."

Who are DermTech's major shareholders?

DermTech's stock is owned by a variety of retail and institutional investors. Top institutional investors include BlackRock Inc. (1.31%), Triatomic Management LP (1.19%), Epiq Partners LLC (0.90%), Geode Capital Management LLC (0.77%), King Luther Capital Management Corp (0.61%) and Woodmont Investment Counsel LLC (0.38%). Insiders that own company stock include Burkhard Jansen, Claudia Ibarra, Enrico Picozza, Herm Rosenman, John Dobak, Kevin M Sun, Kevin M Sun, Matthew L Posard, Mutual Insurance Co Donegal, Ramin Akhavan, Rtw Investments, Lp, Scott R Pancoast and Todd Michael Wood.
View institutional ownership trends
.

How do I buy shares of DermTech?

Shares of DMTK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is DermTech's stock price today?

One share of DMTK stock can currently be purchased for approximately $1.65.

How much money does DermTech make?

DermTech (NASDAQ:DMTK) has a market capitalization of $55.61 million and generates $14.52 million in revenue each year. The company earns $-116,680,000.00 in net income (profit) each year or ($3.90) on an earnings per share basis.

How many employees does DermTech have?

The company employs 278 workers across the globe.

How can I contact DermTech?

DermTech's mailing address is 11099 N. Torrey Pines Road Suite 100, La Jolla CA, 92037. The official website for the company is www.dermtech.com. The company can be reached via phone at (858) 450-4222 or via email at investorrelations@dermtech.com.

This page (NASDAQ:DMTK) was last updated on 9/23/2023 by MarketBeat.com Staff

My Account -